课题基金 / 基金详情

Mechanisms of Beta-blocker Induced Improvements in Asthma

Mechanisms of Beta-blocker Induced Improvements in Asthma
β-受体阻滞剂改善哮喘的机制
批准号:
8447690
负责人:
RICHARD Agustin BOND
金额:
$44.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-15 至 2014-09-30

项目摘要

项目成果

RICHARD Agustin BOND的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Asthma is characterized by reversible airway obstruction, airway hyperresponsiveness (AHR) and airway inflammation. The medications used for control and acute relief of asthma vary in their effectiveness and may produce serious side effects. Thus, there is a need to develop new and improved medications for asthma. Our research has shown that, unexpectedly, activation of the ¿2AR is necessary for the development of the asthma phenotype produced by antigen challenge or by direct intra-tracheal administration of IL-13. We have also shown that chronic treatment of mouse models of asthma with ¿2AR-inverse agonists produced broad anti- inflammatory effects in the airways, including dramatic changes in airway epithelium mucus production and morphology. These data suggest that ¿2ARs located on the airway epithelium may be a key target for the effect of ¿2AR inverse agonists. Our long-range goal is to determine the mechanism of the proasthamtic effect of ¿2AR signaling. To do this we need to understand the signaling pathways and their sites of action. In this project, we will: Aim 1. Test the hypothesis that an important target of ¿2AR-inverse agonists is the airway epithelium, and determine what components of the asthma phenotype are due to lung parenchymal cells versus hematopoietic cells by using genetically altered mice and bone marrow transplantation experiments. Aim 2. Determine the role of ¿2AR-¿-arrestin-2-MAPK signaling, in mediating the pro-asthmatic effects of the ¿2AR using genetically altered mice and human bronchial airway epithelial cells, and Aim 3. Using pharmacological and genetic 'sympathectomy', as well as bone marrow transplant experiments, determine the cellular source of the epinephrine activating the ¿2AR allowing its various pro-asthmatic effects, and because weeks of treatment required for the anti-asthmatic effect of ¿2AR-inverse agonists, we will perform microarray analysis for gene expression changes as a lead for possible mechanisms of action. This research could lead to safer and more efficacious drugs for the treatment of asthma, and alter our understanding of asthma at a paradigm-shifting level.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Biased Beta2-AR Ligands as Asthma Therapeutics
  • 批准号:
    10581573
  • 项目类别:
  • 资助金额:
    $62.99万
  • 财政年份:
    2021
  • 负责人:
    RICHARD Agustin BOND
  • 依托单位:
Novel Biased Beta2-AR Ligands as Asthma Therapeutics
  • 批准号:
    10372196
  • 项目类别:
  • 资助金额:
    $61.53万
  • 财政年份:
    2021
  • 负责人:
    RICHARD Agustin BOND
  • 依托单位:
Optimizing Beta-Adrenoceptor Signaling Bias in Asthma
  • 批准号:
    8770676
  • 项目类别:
  • 资助金额:
    $71.08万
  • 财政年份:
    2014
  • 负责人:
    RICHARD Agustin BOND
  • 依托单位:
Optimizing Beta-Adrenoceptor Signaling Bias in Asthma
  • 批准号:
    9275916
  • 项目类别:
  • 资助金额:
    $61.49万
  • 财政年份:
    2014
  • 负责人:
    RICHARD Agustin BOND
  • 依托单位:
海外基金